New GSK maintains strong start, but Zantac litigation looms large
Source: Reuters
Q3 profit, sales beat expectationsCompany raises 2022 forecast for second time in four monthsIncurs 45 mln pound charge in Q3, primarily linked to ZantacNov 2 (Reuters) - GSK (GSK.L) raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer…